Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Ashish Sarraju, Jingwei Li, Christopher P. Cannon, Tara I. Chang, Rajiv Agarwal, George L. Bakris, David M. Charytan, Dick de Zeeuw, Tom Greene, Hiddo J.L. Heerspink, Adeera Levin, Bruce Neal, Carol A. Pollock, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey